
Thursday, November 01, 2018—Pharmaceutical grade cannabidiol (CBD) (Epidiolex; Greenwich Biosciences, Carlsbad, CA), approved by the FDA for treatment of patients age 2 and up with Lennox-Gastaut Syndrom…
Friday, October 05, 2018—A potentially disease-modifying therapy for Dravet syndrome (DS) being developed by Stoke Therapeutics (Bedford, MA) uses targeted augmentation of nuclear gene output (TANGO) …
Monday, October 01, 2018—The Food and Drug Administration (FDA) has approved perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) for use in children age 4 to 12 years. Before this decision, perampanel was…
Friday, September 28, 2018—The FDA-approved formulation of cannabidiol (CBD)(Epidiolex; GW Pharma, Carlsbad, CA) has been rescheduled by the Drug Enforcement Agency (DEA), clearing the way for marketing…
October 2018—New treatments—from cannabinoids to deep brain stimulation—may help meet the needs of still too many patients with uncontrolled seizures.
October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.
October 2018—Neurosurgical techniques are effective and underutilized for patients with drug-resistant epilepsy.
October 2018—From the vagal nerve to the deep brain, neuromodulation provides another treatment option for patients with epilepsy.
For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com
Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.
We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.
Continue »